{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:44:58Z","timestamp":1776084298293,"version":"3.50.1"},"reference-count":76,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Minister of Science"},{"name":"European Joint Programme on Rare Diseases"},{"name":"Poland The National Centre for Research and Development","award":["EJPRD\/V\/15\/OptiMyG\/2026"],"award-info":[{"award-number":["EJPRD\/V\/15\/OptiMyG\/2026"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Myasthenia gravis (MG) is a rare autoimmune disorder characterized by muscle weakness and fatigue, caused by autoantibodies produced by B-cells that target proteins in the postsynaptic membrane of the neuromuscular junction. Clinical manifestations are heterogeneous and may include diplopia, ptosis, dysarthria, dysphagia, and limb muscle weakness, with severity ranging from mild symptoms to life-threatening myasthenic crisis. Despite advances in diagnostic approaches and the availability of immunomodulatory and biological therapies, there remains a need for an improved understanding of the disease mechanisms and biomarker development in MG. Blood-derived exosomes are small extracellular vesicles that carry proteins, lipids, nucleic acids, and glycoconjugates, and are involved in intercellular communication and the transfer of biological material between cells. Circulating exosomes may reflect aspects of cellular and immune status and have been proposed as a minimally invasive source of biomarkers in various diseases. In this review, we summarize current evidence on the potential role of exosomes in MG, with a focus on their involvement in disease-associated processes and their possible utility as biomarkers, as well as directions for future research.<\/jats:p>","DOI":"10.3390\/cells15080679","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:38:26Z","timestamp":1776080306000},"page":"679","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exosomes in Myasthenia Gravis\u2014Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6427-5798","authenticated-orcid":false,"given":"Krystian","family":"Ejdys","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurosurgery, Laboratory of Neuroimmunology, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-1784","authenticated-orcid":false,"given":"Marcin P.","family":"Mycko","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Laboratory of Neuroimmunology, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1212\/WNL.0000000000202945","article-title":"Incidence and Prevalence of Myasthenia Gravis in the United States: A Claims-Based Analysis (S19.007)","volume":"100","author":"Rodrigues","year":"2023","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","article-title":"Epidemiology and Treatment of Myasthenia Gravis: A Retrospective Study Using a Large Insurance Claims Dataset in Germany","volume":"33","author":"Mevius","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_4","first-page":"e1171","article-title":"Clinical and Therapeutic Features of Myasthenia Gravis in Adults Based on Age at Onset","volume":"94","author":"Segovia","year":"2020","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic Crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101969","DOI":"10.1016\/j.disamonth.2025.101969","article-title":"Myasthenia Gravis: Mechanisms, Clinical Syndromes, and Diagnosis","volume":"71","author":"Fecto","year":"2025","journal-title":"Disease-a-Month"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia Gravis: Recommendations for Clinical Research Standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.31688\/ABMU.2021.56.2.04","article-title":"Characterization of Myasthenia Gravis Using Clinical Classification and Repetitive Nerve Stimulation","volume":"56","author":"Pham","year":"2021","journal-title":"Arch. Balk. Med. Union"},{"key":"ref_9","unstructured":"(2025, May 04). Table 2, Myasthenia Gravis Foundation of America Clinical Classification\u2014Emerging Drugs for Generalized Myasthenia Gravis\u2014NCBI Bookshelf, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK595385\/table\/t02\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis","volume":"392","author":"Nowak","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in Myasthenia Gravis Clinical Research and Care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_12","unstructured":"MGNet (2026, January 25). Myasthenia Gravis Quality of Life-15 Revised (MG-QOL15R). Available online: https:\/\/mgnet.rarediseasesnetwork.org\/sites\/default\/files\/2023-04\/mg-quality-life-15-revised.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jocn.2021.07.020","article-title":"Evaluation of Outcome Measures for Myasthenia Gravis Subgroups","volume":"91","author":"Luo","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"ref_14","unstructured":"(2026, January 25). RESOURCES FOR PROFESSIONALS|Myasthenia Gravis Foundation of America. Available online: https:\/\/myasthenia.org\/professionals\/resources-for-professionals\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/mus.28417","article-title":"Standardization of Myasthenia Gravis Outcome Measures in Clinical Practice: A Report of the MGFA Task Force","volume":"72","author":"Ruzhansky","year":"2025","journal-title":"Muscle Nerve"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/B978-0-12-823912-4.00026-8","article-title":"Myasthenia Gravis\u2014Pathophysiology, Diagnosis, and Treatment","volume":"200","author":"Tannemaat","year":"2024","journal-title":"Handb. Clin. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical Features, Pathogenesis, and Treatment of Myasthenia Gravis: A Supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/jnnp-2024-333920","article-title":"Cyclophosphamide for Myasthenia Gravis: A Comeback?","volume":"95","author":"Katzberg","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia Gravis: An Update for the Clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s10072-021-05823-w","article-title":"Myasthenia Gravis Exacerbation and Myasthenic Crisis Associated with COVID-19: Case Series and Literature Review","volume":"43","author":"Rodrigues","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Vesperinas-Castro, A., and Cort\u00e9s-Vicente, E. (2023). Rituximab Treatment in Myasthenia Gravis. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1275533"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70418","DOI":"10.1111\/ene.70418","article-title":"Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial","volume":"32","author":"Wu","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2147\/NDT.S374694","article-title":"Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence","volume":"19","author":"Vu","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40265-023-01877-6","article-title":"Ravulizumab: A Review in Generalised Myasthenia Gravis","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and Efficacy of Zilucoplan in Patients with Generalised Myasthenia Gravis (RAISE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc Receptor Antagonist Efgartigimod Safely and Sustainably Reduces IgGs in Humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and Efficacy of Rozanolixizumab in Patients with Generalised Myasthenia Gravis (MycarinG): A Randomised, Double-Blind, Placebo-Controlled, Adaptive Phase 3 Study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s40265-025-02211-y","article-title":"Nipocalimab: First Approval","volume":"85","author":"Fung","year":"2025","journal-title":"Drugs"},{"key":"ref_33","unstructured":"(2026, January 25). FDA Approves Inebilizumab for Generalized Myasthenia Gravis|AJMC. Available online: https:\/\/www.ajmc.com\/view\/fda-approves-inebilizumab-for-generalized-myasthenia-gravis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International Consensus Guidance for Management of Myasthenia Gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Krylova, S.V., and Feng, D. (2023). The Machinery of Exosomes: Biogenesis, Release, and Uptake. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021337"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.7150\/thno.52570","article-title":"Engineering Exosomes for Targeted Drug Delivery","volume":"11","author":"Liang","year":"2021","journal-title":"Theranostics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/1352458519879303","article-title":"MicroRNA and Exosome Profiling in Multiple Sclerosis","volume":"26","author":"Mycko","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2017.02.002","article-title":"The Role of Exosomes in CNS Inflammation and Their Involvement in Multiple Sclerosis","volume":"306","author":"Selmaj","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/bmm.14.9","article-title":"Circulating Microparticles Reflect Treatment Effects and Clinical Status in Multiple Sclerosis","volume":"8","author":"Irizar","year":"2014","journal-title":"Biomark. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1352458517696597","article-title":"Multiple Sclerosis: Serum-Derived Exosomes Express Myelin Proteins","volume":"24","author":"Galazka","year":"2018","journal-title":"Mult. Scler. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1002\/mco2.660","article-title":"Exosome Nanovesicles: Biomarkers and New Strategies for Treatment of Human Diseases","volume":"5","author":"Xu","year":"2024","journal-title":"MedComm"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jamasurg.2025.2493","article-title":"Exosomal Liquid Biopsy for the Early Detection of Gastric Cancer: The DESTINEX Multicenter Study","volume":"160","author":"Sui","year":"2025","journal-title":"JAMA Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.7150\/thno.106459","article-title":"Advances in Subpopulation Separation and Detection of Extracellular Vesicles: For Liquid Biopsy and Downstream Research","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7150\/ijbs.53671","article-title":"Regulation of Exosome Production and Cargo Sorting","volume":"17","author":"Wei","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Han, Z., Chen, H., Guo, Z., Shen, J., Luo, W., Xie, F., Wan, Y., Wang, S., Li, J., and He, J. (2022). Circular RNAs and Their Role in Exosomes. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.848341"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Yu, X., Odenthal, M., and Fries, J.W.U. (2016). Exosomes as MiRNA Carriers: Formation\u2013Function\u2013Future. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122028"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gpb.2015.02.001","article-title":"Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function","volume":"13","author":"Zhang","year":"2015","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.plipres.2017.03.001","article-title":"Lipids in Exosomes: Current Knowledge and the Way Forward","volume":"66","author":"Skotland","year":"2017","journal-title":"Prog. Lipid Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bbalip.2013.04.011","article-title":"Molecular Lipidomics of Exosomes Released by PC-3 Prostate Cancer Cells","volume":"1831","author":"Llorente","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1186\/s12967-024-05817-0","article-title":"Exosomes as Novel Biomarkers in Sepsis and Sepsis Related Organ Failure","volume":"22","author":"Yuan","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-022-01509-9","article-title":"Exosomes as a New Frontier of Cancer Liquid Biopsy","volume":"21","author":"Yu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13195-022-01133-1","article-title":"Proteomic Profiling of Circulating Plasma Exosomes Reveals Novel Biomarkers of Alzheimer\u2019s Disease","volume":"14","author":"Cai","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/08820139.2024.2440772","article-title":"The Role of Exosomes in Central Immune Tolerance and Myasthenia Gravis","volume":"54","author":"Zhang","year":"2025","journal-title":"Immunol. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.imlet.2016.02.005","article-title":"Altered Expression of MiR-125a-5p in Thymoma-Associated Myasthenia Gravis and Its down-Regulation of Foxp3 Expression in Jurkat Cells","volume":"172","author":"Li","year":"2016","journal-title":"Immunol. Lett."},{"key":"ref_55","first-page":"1070","article-title":"Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions","volume":"14","author":"Huang","year":"2023","journal-title":"Aging Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Fiorillo, A.A., Heier, C.R., Huang, Y.F., Tully, C.B., Punga, T., and Punga, A.R. (2020). Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating MicroRNAs. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00151"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"MiR-30e-5p as Predictor of Generalization in Ocular Myasthenia Gravis","volume":"6","author":"Sabre","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating MiRNAs in Myasthenia Gravis: MiR-150-5p as a New Potential Biomarker","volume":"1","author":"Punga","year":"2013","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mus.26785","article-title":"Plasma Exosomal MiR-106a-5p Expression in Myasthenia Gravis","volume":"61","author":"Xu","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_60","first-page":"277","article-title":"MiR-9-5p and MiR-106a-5p Dysregulated in CD4+ T-Cells of Multiple Sclerosis Patients and Targeted Essential Factors of T Helper17\/Regulatory T-Cells Differentiation","volume":"21","author":"Majd","year":"2018","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy Lowers the Myasthenia Gravis Biomarker MiR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.21037\/jtd.2019.08.109","article-title":"Unraveling the Role of Ectopic Thymic Tissue in Patients Undergoing Thymectomy for Myasthenia Gravis","volume":"11","author":"Li","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Cron, M.A., Maillard, S., Truffault, F., Gualeni, A.V., Gloghini, A., Fadel, E., Guihaire, J., Behin, A., Berrih-Aknin, S., and Le Panse, R. (2019). Causes and Consequences of MiR-150-5p Dysregulation in Myasthenia Gravis. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00539"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.gene.2018.04.065","article-title":"MYB\u2014A Regulatory Factor in Hematopoiesis","volume":"665","author":"Wang","year":"2018","journal-title":"Gene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ana.410410609","article-title":"Altered Intrathymic T-Cell Repertoire in Human Myasthenia Gravis","volume":"41","author":"Truffault","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"313ra178","DOI":"10.1126\/scitranslmed.aad2722","article-title":"A Validated Gene Regulatory Network and GWAS Identifies Early Regulators of T Cell-Associated Diseases","volume":"7","author":"Gustafsson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"148034","DOI":"10.1016\/j.gene.2023.148034","article-title":"Study of Serum Exosome MiRNA as a Biomarker for Early Onset Adult Ouclar Myastthenia Gravis","volume":"896","author":"Mu","year":"2024","journal-title":"Gene"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/postmj\/qgae015","article-title":"Small Extracellular Vesicle MicroRNAs in Pediatric Myasthenia Gravis Plasma and Skeletal Muscle","volume":"100","author":"Zhu","year":"2024","journal-title":"Postgrad. Med. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e23722","DOI":"10.1002\/jcla.23722","article-title":"Expression Profiling and Bioinformatics Analysis of Exosomal Long Noncoding RNAs in Patients with Myasthenia Gravis by RNA Sequencing","volume":"35","author":"Lu","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"577383","DOI":"10.1016\/j.jneuroim.2020.577383","article-title":"Low-Dose Rituximab Lowers Serum Exosomal MiR-150-5p in AChR-Positive Refractory Myasthenia Gravis Patients","volume":"348","author":"Zhong","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/mus.27233","article-title":"Short-Term Effect of Low-Dose Rituximab on Myasthenia Gravis with Muscle-Specific Tyrosine Kinase Antibody","volume":"63","author":"Zhou","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6180","DOI":"10.1038\/s41388-021-02011-0","article-title":"MiR-151a-3p-Rich Small Extracellular Vesicles Derived from Gastric Cancer Accelerate Liver Metastasis via Initiating a Hepatic Stemness-Enhancing Niche","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s10753-017-0589-2","article-title":"Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis","volume":"40","author":"Yin","year":"2017","journal-title":"Inflammation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12974-016-0475-0","article-title":"Exosomes Derived from Atorvastatin-Modified Bone Marrow Dendritic Cells Ameliorate Experimental Autoimmune Myasthenia Gravis by up-Regulated Levels of IDO\/Treg and Partly Dependent on FasL\/Fas Pathway","volume":"13","author":"Li","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12974-019-1587-0","article-title":"Exosomes Derived from Statin-Modified Bone Marrow Dendritic Cells Increase Thymus-Derived Natural Regulatory T Cells in Experimental Autoimmune Myasthenia Gravis","volume":"16","author":"Zhang","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2015.04.009","article-title":"Immature Dendritic Cell Exosomes Suppress Experimental Autoimmune Myasthenia Gravis","volume":"285","author":"Bu","year":"2015","journal-title":"J. Neuroimmunol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/8\/679\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:49:02Z","timestamp":1776080942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/8\/679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":76,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cells15080679"],"URL":"https:\/\/doi.org\/10.3390\/cells15080679","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}